drugset / Trial / NCT04213404
Ribociclib and Spartalizumab in R/M HNSCC
NaSingle-groupOpen-labelTreatment
Summary
This study examines the safety and efficacy of ribociclib (CDK 4/6 inhibitors) and spartalizumab (anti-PD1) in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Timeline
- Start
- 2020-03-13
- Primary completion
- 2024-01
- Completion
- 2025-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ribociclib | Small molecule | 200 mg | Oral |
| Subject | Ribociclib | Small molecule | 400 mg | Oral |
| Subject | Ribociclib | Small molecule | 600 mg | Oral |
| Subject | Spartalizumab | Monoclonal antibody | 400 mg | Intravenous |